Please try another search
For the fiscal year ended 31 December 2021, SLS Bio Co Ltd revenues decreased 5% to W8.24B. Net income totaled W57.9M vs. loss of W677.9M. Revenues reflect Medication quality control segment decrease of 6% to W6.86B, New Drug Development Support segment decrease of 14% to W1.13B. Net Income reflects Expense of Allow for DA decrease of 92% to W56.5M (expense), Retirement & Severance Benefits decrease of 85% to W73.8M (expense).
Period Ending: | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Revenue | 8242.51 | 8722.04 | 7420.06 | 6354.63 |
Gross Profit | 2179.2 | 2251 | 2877.03 | 1969.86 |
Operating Income | 426.23 | -715.44 | 1083.88 | 549.22 |
Net Income | 57.89 | -677.92 | 626.93 | -2923.47 |
Period Ending: | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Assets | 10505.93 | 10134.52 | 11082.89 | 6977.7 |
Total Liabilities | 6782.1 | 6596.88 | 6941.96 | 4849.84 |
Total Equity | 3723.83 | 3537.63 | 4140.93 | 2127.86 |
Period Ending: | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Period Length: | 12 Months | 12 Months | 12 Months | 12 Months |
Cash From Operating Activities | 2257.6 | 677.67 | 1994.65 | -245.3 |
Cash From Investing Activities | -782.31 | -541.36 | 294.48 | -1553.09 |
Cash From Financing Activities | -185.66 | -722.22 | -1904.36 | 667.47 |
Net Change in Cash | 1289.87 | -585.91 | 384.76 | -1130.92 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review